Mahevas M, Vaida I, Le Page L, Sid-Idris S, Royer B, Garedi R, Damaj G, Duhaut P, Claisse J-F, Ducroix J-P, Marolleau J-P
Service de médecine interne, hôpital Nord, CHU d'Amiens, place Victor-Pauchet, 80054 Amiens cedex 1, France.
Rev Med Interne. 2008 Feb;29(2):115-21. doi: 10.1016/j.revmed.2007.08.008. Epub 2007 Sep 21.
During the past ten years, more than 1000 patients suffering from severe autoimmune disease have received an autologous haematopoietic stem cell transplant. These new therapeutic have been used in systemic sclerosis (scleroderma), multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis and systemic lupus erythematosus.
Autologous haematopoietic stem cell transplantation has become a curative option for condition with very poor prognosis as severe systemic sclerosis, lupus erythematosus or other systemic diseases. This review summarizes the current experience in the phase I and II clinical trials in Europe and North America. We describe the main results and the limits of stem cell transplantation in systemic diseases.
Autologous haematopoietic stem cell transplant in the treatment of autoimmune disease has evolved from a experimental concept to a clinically feasible and powerful therapy for selected patients with severe disease.
在过去十年中，超过1000名患有严重自身免疫性疾病的患者接受了自体造血干细胞移植。这些新疗法已应用于系统性硬化症（硬皮病）、多发性硬化症、类风湿性关节炎、幼年特发性关节炎和系统性红斑狼疮。
自体造血干细胞移植已成为严重系统性硬化症、红斑狼疮或其他系统性疾病等预后极差病症的一种治愈性选择。本综述总结了欧洲和北美的I期和II期临床试验的当前经验。我们描述了系统性疾病中干细胞移植的主要结果和局限性。
自体造血干细胞移植治疗自身免疫性疾病已从一个实验性概念发展成为一种对选定的重症患者临床可行且有效的疗法。
Zotero 插件